Cerebras Systems, a Sunnyvale-based maker of high-performance AI processors, filed for a U.S. initial public offering on April 17, 2026, aiming to list on Nasdaq under the ticker CBRS. The filing follows a 2024 funding round that raised more than $1 billion and valued the company at roughly $8 billion, and comes as the IPO market shows renewed momentum. Cerebras reported revenue of $510 million in 2025 and a turnaround to net income of about $238 million after a 2024 loss. The company says its wafer-scale engine offers substantially larger die size and far greater memory bandwidth than many competing designs and has secured partnerships or deals with major cloud and AI players, including Amazon Web Services and OpenAI. Lead underwriters for the offering are Morgan Stanley, Citigroup, Barclays and UBS. Earlier disclosures showed heavy revenue concentration with G42 accounting for a large share of sales in 2024, a point investors will scrutinize. The filing arrives amid expectations of several high-profile tech listings that could compete for investor attention.

A federal judge in Sacramento issued a preliminary injunction on April 17-18, 2026, barring Nexstar Media Group from integrating recently acquired Tegna stations while antitrust litigation proceeds. Chief U.S. District Judge Troy L. Nunley found plaintiffs — DirecTV and a coalition of eight state attorneys general led by California’s Rob Bonta and New York’s Letitia James — likely to succeed on claims that the roughly $6.2 billion deal would substantially lessen competition in local television markets. The order does not unwind the March 19 closing, which followed approvals and limited waivers from the Federal Communications Commission and the Justice Department, but requires Nexstar to maintain Tegna as a separate, economically viable business unit and refrain from consolidating operations. Plaintiffs argue the tie-up, which gives Nexstar control of about 265 stations reaching roughly 80% of U.S. households, would raise retransmission fees, threaten local newsrooms and enable leverage over pay-TV providers (including potential blackouts of NFL games). Nexstar said it will appeal to the Ninth Circuit. The injunction takes effect April 21 and the case will proceed to trial, where defeat could force an unwind of the transaction.

Kailera Therapeutics raised $625 million in an initial public offering and began trading on Nasdaq on April 17, 2026 under the ticker KLRA. The biotech sold roughly 39.06 million shares at $16 each and the stock opened at $26, a surge of about 62.5% from the offering price. The deal, one of the largest biotech IPOs in recent years, pushed the company’s valuation into the low billions after the first-day pop. Kailera is developing multiple GLP-1–class obesity treatments, including a global Phase 3 injectible GLP-1/GIP candidate and an oral GLP-1 program; key late-stage readouts for the lead program are not expected until 2028. Backers include prominent venture investors such as Bain Capital, Atlas Venture and Arch Venture Partners. The listing underscores strong investor appetite for obesity drugs as established players like Novo Nordisk and Eli Lilly dominate a market projected to reach roughly $150 billion annually by the end of the decade.

Spirit Airlines has asked the U.S. administration for hundreds of millions of dollars in emergency aid as a sharp rise in jet fuel prices threatens its planned exit from bankruptcy, Reuters and other outlets reported on April 16-17, 2026. The carrier is due to meet Transportation Secretary Sean Duffy next week after the Department of Transportation requested a review of the financial health of smaller U.S. carriers. Spirit, which filed for Chapter 11 twice (most recently in August 2025), is pursuing a deep restructuring that would shrink its fleet to about 76-80 aircraft by mid-2026. The company built its turnaround on fuel assumptions near $2.20 a gallon; mid-April jet fuel traded around $4.20–$4.88 a gallon after the war in Iran, prompting JP Morgan to estimate an incremental $360 million hit and a potential 2026 operating margin near negative 20%. Creditors including Citibank have objected to Spirit’s reorganisation projections and warned that defaults could lead to collateral repossession and possible liquidation, though sources say immediate shutdown is not the most likely outcome. Spirit says it continues to operate normally.

Alamar Biosciences fetched a $1.53 billion valuation after its Nasdaq debut on April 17, 2026, when shares opened at $22.60 versus an offer price of $17, a roughly 33% first-day gain. The Fremont, California-based proteomics company sold about 11.3 million shares in an upsized offering at the top of its marketed range, raising roughly $191.3 million. Founded in 2018, Alamar develops the NULISA-based precision proteomics platform to detect low-level protein biomarkers for neurology, immunology and other disease areas; revenue grew to just over $74 million in 2025, roughly triple year-on-year. Market commentary linked the successful listing to a revived IPO market as geopolitical tensions eased. Independent market reports also noted institutional interest following the listing, including a reported purchase of 537,500 shares by ARK Investment Management. Some post-IPO coverage flagged limited historical financial metrics — no meaningful P/E and proprietary scorecards that lack data — underscoring early-stage risks despite strong investor demand.

India’s Directorate General of Foreign Trade on April 17 issued a delayed order naming 15 banks authorised by the Reserve Bank of India to import gold and silver from April 1, 2026 to March 31, 2029, ending a hold-up that forced banks to halt new bullion purchases. The list, which did not explain the delay, allows major lenders including State Bank of India, HDFC Bank and Bank of India to import both metals; Union Bank of India and Sberbank are permitted to import only gold. Traders had reported more than 5 metric tonnes of gold and about 8 tonnes of silver stuck at customs while awaiting clearance, and banks had paused fresh overseas orders. The disruption coincided with preparations for the Akshaya Tritiya festival and came amid wider government efforts to manage the trade deficit as oil and other import costs rise. Market sources said inventories had drawn down and jewellery demand, ETF flows and premiums could be affected until customs clearances resume.